Literature DB >> 21146621

Predictive markers for AD in a multi-modality framework: an analysis of MCI progression in the ADNI population.

Chris Hinrichs1, Vikas Singh, Guofan Xu, Sterling C Johnson.   

Abstract

Alzheimer's Disease (AD) and other neurodegenerative diseases affect over 20 million people worldwide, and this number is projected to significantly increase in the coming decades. Proposed imaging-based markers have shown steadily improving levels of sensitivity/specificity in classifying individual subjects as AD or normal. Several of these efforts have utilized statistical machine learning techniques, using brain images as input, as means of deriving such AD-related markers. A common characteristic of this line of research is a focus on either (1) using a single imaging modality for classification, or (2) incorporating several modalities, but reporting separate results for each. One strategy to improve on the success of these methods is to leverage all available imaging modalities together in a single automated learning framework. The rationale is that some subjects may show signs of pathology in one modality but not in another-by combining all available images a clearer view of the progression of disease pathology will emerge. Our method is based on the Multi-Kernel Learning (MKL) framework, which allows the inclusion of an arbitrary number of views of the data in a maximum margin, kernel learning framework. The principal innovation behind MKL is that it learns an optimal combination of kernel (similarity) matrices while simultaneously training a classifier. In classification experiments MKL outperformed an SVM trained on all available features by 3%-4%. We are especially interested in whether such markers are capable of identifying early signs of the disease. To address this question, we have examined whether our multi-modal disease marker (MMDM) can predict conversion from Mild Cognitive Impairment (MCI) to AD. Our experiments reveal that this measure shows significant group differences between MCI subjects who progressed to AD, and those who remained stable for 3 years. These differences were most significant in MMDMs based on imaging data. We also discuss the relationship between our MMDM and an individual's conversion from MCI to AD.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21146621      PMCID: PMC3035743          DOI: 10.1016/j.neuroimage.2010.10.081

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  51 in total

Review 1.  Neuropathology of Alzheimer's disease: what is new since A. Alzheimer?

Authors:  E Braak; K Griffing; K Arai; J Bohl; H Bratzke; H Braak
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1999       Impact factor: 5.270

Review 2.  Cerebral blood flow and metabolic abnormalities in Alzheimer's disease.

Authors:  H Matsuda
Journal:  Ann Nucl Med       Date:  2001-04       Impact factor: 2.668

3.  Comparison of gray matter and metabolic reduction in mild Alzheimer's disease using FDG-PET and voxel-based morphometric MR studies.

Authors:  Kazunari Ishii; Hiroki Sasaki; Atsushi K Kono; Naokazu Miyamoto; Tetsuya Fukuda; Etsuro Mori
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-31       Impact factor: 9.236

Review 4.  Computational anatomical methods as applied to ageing and dementia.

Authors:  P M Thompson; L G Apostolova
Journal:  Br J Radiol       Date:  2007-12       Impact factor: 3.039

5.  Automatic classification of patients with Alzheimer's disease from structural MRI: a comparison of ten methods using the ADNI database.

Authors:  Rémi Cuingnet; Emilie Gerardin; Jérôme Tessieras; Guillaume Auzias; Stéphane Lehéricy; Marie-Odile Habert; Marie Chupin; Habib Benali; Olivier Colliot
Journal:  Neuroimage       Date:  2010-06-11       Impact factor: 6.556

6.  FDG PET imaging in patients with pathologically verified dementia.

Authors:  J M Hoffman; K A Welsh-Bohmer; M Hanson; B Crain; C Hulette; N Earl; R E Coleman
Journal:  J Nucl Med       Date:  2000-11       Impact factor: 10.057

7.  Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease.

Authors:  K B Walhovd; A M Fjell; J Brewer; L K McEvoy; C Fennema-Notestine; D J Hagler; R G Jennings; D Karow; A M Dale
Journal:  AJNR Am J Neuroradiol       Date:  2010-01-14       Impact factor: 3.825

8.  Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index.

Authors:  Christos Davatzikos; Feng Xu; Yang An; Yong Fan; Susan M Resnick
Journal:  Brain       Date:  2009-05-04       Impact factor: 13.501

9.  A projection pursuit algorithm to classify individuals using fMRI data: Application to schizophrenia.

Authors:  Oguz Demirci; Vincent P Clark; Vince D Calhoun
Journal:  Neuroimage       Date:  2008-02-15       Impact factor: 6.556

10.  Automatic classification of MR scans in Alzheimer's disease.

Authors:  Stefan Klöppel; Cynthia M Stonnington; Carlton Chu; Bogdan Draganski; Rachael I Scahill; Jonathan D Rohrer; Nick C Fox; Clifford R Jack; John Ashburner; Richard S J Frackowiak
Journal:  Brain       Date:  2008-01-17       Impact factor: 13.501

View more
  153 in total

1.  Identifying quantitative trait loci via group-sparse multitask regression and feature selection: an imaging genetics study of the ADNI cohort.

Authors:  Hua Wang; Feiping Nie; Heng Huang; Sungeun Kim; Kwangsik Nho; Shannon L Risacher; Andrew J Saykin; Li Shen
Journal:  Bioinformatics       Date:  2011-12-06       Impact factor: 6.937

Review 2.  Understanding cognitive deficits in Alzheimer's disease based on neuroimaging findings.

Authors:  Meredith N Braskie; Paul M Thompson
Journal:  Trends Cogn Sci       Date:  2013-09-09       Impact factor: 20.229

3.  Identification of Alzheimer's disease and mild cognitive impairment using multimodal sparse hierarchical extreme learning machine.

Authors:  Jongin Kim; Boreom Lee
Journal:  Hum Brain Mapp       Date:  2018-05-07       Impact factor: 5.038

4.  Multimodal analysis of functional and structural disconnection in Alzheimer's disease using multiple kernel SVM.

Authors:  Martin Dyrba; Michel Grothe; Thomas Kirste; Stefan J Teipel
Journal:  Hum Brain Mapp       Date:  2015-02-09       Impact factor: 5.038

5.  Magnetization-prepared rapid acquisition with gradient echo magnetic resonance imaging signal and texture features for the prediction of mild cognitive impairment to Alzheimer's disease progression.

Authors:  Antonio Martinez-Torteya; Juan Rodriguez-Rojas; José M Celaya-Padilla; Jorge I Galván-Tejada; Victor Treviño; Jose Tamez-Peña
Journal:  J Med Imaging (Bellingham)       Date:  2014-09-15

6.  Amyloid-β Positivity Predicts Cognitive Decline but Cognition Predicts Progression to Amyloid-β Positivity.

Authors:  Jeremy A Elman; Matthew S Panizzon; Daniel E Gustavson; Carol E Franz; Mark E Sanderson-Cimino; Michael J Lyons; William S Kremen
Journal:  Biol Psychiatry       Date:  2020-01-07       Impact factor: 13.382

Review 7.  Neuroimaging-based methods for autism identification: a possible translational application?

Authors:  Alessandra Retico; Michela Tosetti; Filippo Muratori; Sara Calderoni
Journal:  Funct Neurol       Date:  2014 Oct-Dec

8.  Inter-modality relationship constrained multi-modality multi-task feature selection for Alzheimer's Disease and mild cognitive impairment identification.

Authors:  Feng Liu; Chong-Yaw Wee; Huafu Chen; Dinggang Shen
Journal:  Neuroimage       Date:  2013-09-14       Impact factor: 6.556

9.  Randomized denoising autoencoders for smaller and efficient imaging based AD clinical trials.

Authors:  Vamsi K Ithapul; Vikas Singh; Ozioma Okonkwo; Sterling C Johnson
Journal:  Med Image Comput Comput Assist Interv       Date:  2014

10.  Label-aligned multi-task feature learning for multimodal classification of Alzheimer's disease and mild cognitive impairment.

Authors:  Chen Zu; Biao Jie; Mingxia Liu; Songcan Chen; Dinggang Shen; Daoqiang Zhang
Journal:  Brain Imaging Behav       Date:  2016-12       Impact factor: 3.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.